Entrada Therapeutics (TRDA)
(Real Time Quote from BATS)
$5.74 USD
-0.09 (-1.54%)
Updated Aug 6, 2025 02:28 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Entrada Therapeutics, Inc. has a market cap of $221.27M, which represents its share price of $5.83 multiplied by its outstanding shares number of 37.95M. As a small-cap company, TRDA's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
TRDA 5.74 -0.09(-1.54%)
Will TRDA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TRDA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TRDA
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates
Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock?
TRDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates
Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for
Other News for TRDA
Entrada Therapeutics (TRDA) Hits Key Milestone in Duchenne Therapy Trials
Entrada Therapeutics GAAP EPS of -$1.04, revenue of $2M
Entrada Therapeutics Reports Second Quarter 2025 Financial Results | TRDA Stock News
Entrada Therapeutics reports Q2 EPS ($1.04), consensus (86c)
Tracking Baker Brothers Portfolio - Q1 2025 Update